Randomized, non-inferiority trial comparing a nitric oxide releasing solution with a macrolide antibiotic for control of bovine respiratory disease in beef feedlot calves at high-risk of developing respiratory tract disease
Nitric oxide, a molecule produced in most mammalian cells, has bactericidal and virucidal properties. Nasal instillation of a nitric oxide releasing solution (NORS) on arrival at the feedlot was recently reported as non-inferior to a parenteral injection of a macrolide antibiotic, tilmicosin, for co...
Gespeichert in:
Veröffentlicht in: | Research in veterinary science 2016-04, Vol.105, p.216-221 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 221 |
---|---|
container_issue | |
container_start_page | 216 |
container_title | Research in veterinary science |
container_volume | 105 |
creator | Crepieux, T. Miller, C. Regev-Shoshani, G. Schaefer, A. Dorin, C. Alexander, T. Timsit, E. |
description | Nitric oxide, a molecule produced in most mammalian cells, has bactericidal and virucidal properties. Nasal instillation of a nitric oxide releasing solution (NORS) on arrival at the feedlot was recently reported as non-inferior to a parenteral injection of a macrolide antibiotic, tilmicosin, for control of bovine respiratory disease (BRD) in cattle at low-to-moderate risk of developing BRD. The objective of this study was to evaluate whether NORS was non-inferior to tilmicosin for control of BRD in cattle at high-risk of developing BRD (the target population for many BRD control programs). High-risk Angus-cross heifers (n=840) were randomly allocated to 2 treatment groups on arrival at a feedlot and received either NORS or tilmicosin for BRD control. Non-inferiority was assessed by calculating the difference in prevalence of heifers diagnosed with BRD during the first 40d after arrival between NORS and tilmicosin treatment groups. The non-inferiority margin (δ) was set at 8.5%. Thirty-six and 19% of heifers were diagnosed with BRD in the NORS and tilmicosin groups, respectively. Because the lower bound of the 2-sided 95% confidence interval (CI) of the difference in BRD prevalence between the 2 treatment groups (17%; 95% CI=11–23%) was higher than δ, an inferiority of NORS was concluded. Although on-arrival nasal administration of NORS can be viewed as a more rational control strategy than parental injection of antibiotics, further research is needed to improve NORS efficacy before it can be recommended to prevent BRD in high-risk cattle.
•A nitric oxide releasing solution (NORS) has been developed for control of bovine respiratory disease (BRD).•Nasal administration of NORS was compared to parenteral injection of tilmicosin for BRD control in high-risk feedlot cattle.•36% and 19% of cattle were diagnosed with BRD during the 40 d following administration of NORS and tilmicosin, respectively.•An inferiority of NORS compared to tilmicosin was concluded.•NORS efficacy should be improved before it can be recommended to prevent BRD in high-risk cattle. |
doi_str_mv | 10.1016/j.rvsc.2016.02.020 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1805512262</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0034528816300431</els_id><sourcerecordid>1777979699</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-7becf58406be5a3646ee28fa8c23f907cd73656e19c15eecacd27a3fddb8b4ec3</originalsourceid><addsrcrecordid>eNqFks-KFDEQhxtR3NnVF_AgAS8etsck3Z10gxdZ_AcLgug5pJPKTo3dyZhkRseX9VVMM7siHhQCCamvPpLiV1VPGF0zysSL7Toeklnzcl5TXha9V61Y1_CaC8HuVytKm7bueN-fVecpbSmlLWPyYXXGJW2aoRGr6udH7W2Y8QfYS-KDr9E7iBgi5iPJEfVETJh3OqK_IZp4LHeGhO9ogUSYQKelkMK0zxg8-YZ5U7BZmximhdE-44ghlyYXYnH5XCokODKGA_pFknYYdQ7xSCymIgSCnowAjjgAO4VMjJ4OkIjOZIM3mzpi-rIYLBxgCrvlAX9actQm37keVQ-cnhI8vt0vqs9vXn-6eldff3j7_urVdW1aJnMtRzCu61sqRuh0I1oBwHune8MbN1BprGxEJ4ANhnUARhvLpW6ctWM_tmCai-r5ybuL4eseUlYzJgPTpD2EfVKsp13HOBf8_6iUcpCDGIaCPvsL3YZ99OUjRbhgQye6QvETVYaeUgSndhFnHY-KUbUkRW3VkhS1JEVRXhYtTU9v1ftxBvu75S4aBXh5AqCM7YAQVTII3oDFCCYrG_Bf_l_rEtaF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1877799565</pqid></control><display><type>article</type><title>Randomized, non-inferiority trial comparing a nitric oxide releasing solution with a macrolide antibiotic for control of bovine respiratory disease in beef feedlot calves at high-risk of developing respiratory tract disease</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Crepieux, T. ; Miller, C. ; Regev-Shoshani, G. ; Schaefer, A. ; Dorin, C. ; Alexander, T. ; Timsit, E.</creator><creatorcontrib>Crepieux, T. ; Miller, C. ; Regev-Shoshani, G. ; Schaefer, A. ; Dorin, C. ; Alexander, T. ; Timsit, E.</creatorcontrib><description>Nitric oxide, a molecule produced in most mammalian cells, has bactericidal and virucidal properties. Nasal instillation of a nitric oxide releasing solution (NORS) on arrival at the feedlot was recently reported as non-inferior to a parenteral injection of a macrolide antibiotic, tilmicosin, for control of bovine respiratory disease (BRD) in cattle at low-to-moderate risk of developing BRD. The objective of this study was to evaluate whether NORS was non-inferior to tilmicosin for control of BRD in cattle at high-risk of developing BRD (the target population for many BRD control programs). High-risk Angus-cross heifers (n=840) were randomly allocated to 2 treatment groups on arrival at a feedlot and received either NORS or tilmicosin for BRD control. Non-inferiority was assessed by calculating the difference in prevalence of heifers diagnosed with BRD during the first 40d after arrival between NORS and tilmicosin treatment groups. The non-inferiority margin (δ) was set at 8.5%. Thirty-six and 19% of heifers were diagnosed with BRD in the NORS and tilmicosin groups, respectively. Because the lower bound of the 2-sided 95% confidence interval (CI) of the difference in BRD prevalence between the 2 treatment groups (17%; 95% CI=11–23%) was higher than δ, an inferiority of NORS was concluded. Although on-arrival nasal administration of NORS can be viewed as a more rational control strategy than parental injection of antibiotics, further research is needed to improve NORS efficacy before it can be recommended to prevent BRD in high-risk cattle.
•A nitric oxide releasing solution (NORS) has been developed for control of bovine respiratory disease (BRD).•Nasal administration of NORS was compared to parenteral injection of tilmicosin for BRD control in high-risk feedlot cattle.•36% and 19% of cattle were diagnosed with BRD during the 40 d following administration of NORS and tilmicosin, respectively.•An inferiority of NORS compared to tilmicosin was concluded.•NORS efficacy should be improved before it can be recommended to prevent BRD in high-risk cattle.</description><identifier>ISSN: 0034-5288</identifier><identifier>EISSN: 1532-2661</identifier><identifier>DOI: 10.1016/j.rvsc.2016.02.020</identifier><identifier>PMID: 27033936</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Alternative to antibiotics ; Animals ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Bacteria ; Bovine Respiratory Disease Complex - etiology ; Bovine Respiratory Disease Complex - prevention & control ; BRD ; Cattle ; Disease prevention ; Female ; Hypotheses ; Metaphylaxis ; Mortality ; Nitric oxide ; Nitric Oxide - administration & dosage ; Nitric Oxide - therapeutic use ; Prevalence ; Prevention ; Respiratory diseases ; Tilmicosin ; Tylosin - administration & dosage ; Tylosin - analogs & derivatives ; Tylosin - therapeutic use ; Veterinary medicine</subject><ispartof>Research in veterinary science, 2016-04, Vol.105, p.216-221</ispartof><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Apr 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-7becf58406be5a3646ee28fa8c23f907cd73656e19c15eecacd27a3fddb8b4ec3</citedby><cites>FETCH-LOGICAL-c417t-7becf58406be5a3646ee28fa8c23f907cd73656e19c15eecacd27a3fddb8b4ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.rvsc.2016.02.020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27033936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crepieux, T.</creatorcontrib><creatorcontrib>Miller, C.</creatorcontrib><creatorcontrib>Regev-Shoshani, G.</creatorcontrib><creatorcontrib>Schaefer, A.</creatorcontrib><creatorcontrib>Dorin, C.</creatorcontrib><creatorcontrib>Alexander, T.</creatorcontrib><creatorcontrib>Timsit, E.</creatorcontrib><title>Randomized, non-inferiority trial comparing a nitric oxide releasing solution with a macrolide antibiotic for control of bovine respiratory disease in beef feedlot calves at high-risk of developing respiratory tract disease</title><title>Research in veterinary science</title><addtitle>Res Vet Sci</addtitle><description>Nitric oxide, a molecule produced in most mammalian cells, has bactericidal and virucidal properties. Nasal instillation of a nitric oxide releasing solution (NORS) on arrival at the feedlot was recently reported as non-inferior to a parenteral injection of a macrolide antibiotic, tilmicosin, for control of bovine respiratory disease (BRD) in cattle at low-to-moderate risk of developing BRD. The objective of this study was to evaluate whether NORS was non-inferior to tilmicosin for control of BRD in cattle at high-risk of developing BRD (the target population for many BRD control programs). High-risk Angus-cross heifers (n=840) were randomly allocated to 2 treatment groups on arrival at a feedlot and received either NORS or tilmicosin for BRD control. Non-inferiority was assessed by calculating the difference in prevalence of heifers diagnosed with BRD during the first 40d after arrival between NORS and tilmicosin treatment groups. The non-inferiority margin (δ) was set at 8.5%. Thirty-six and 19% of heifers were diagnosed with BRD in the NORS and tilmicosin groups, respectively. Because the lower bound of the 2-sided 95% confidence interval (CI) of the difference in BRD prevalence between the 2 treatment groups (17%; 95% CI=11–23%) was higher than δ, an inferiority of NORS was concluded. Although on-arrival nasal administration of NORS can be viewed as a more rational control strategy than parental injection of antibiotics, further research is needed to improve NORS efficacy before it can be recommended to prevent BRD in high-risk cattle.
•A nitric oxide releasing solution (NORS) has been developed for control of bovine respiratory disease (BRD).•Nasal administration of NORS was compared to parenteral injection of tilmicosin for BRD control in high-risk feedlot cattle.•36% and 19% of cattle were diagnosed with BRD during the 40 d following administration of NORS and tilmicosin, respectively.•An inferiority of NORS compared to tilmicosin was concluded.•NORS efficacy should be improved before it can be recommended to prevent BRD in high-risk cattle.</description><subject>Alternative to antibiotics</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Bovine Respiratory Disease Complex - etiology</subject><subject>Bovine Respiratory Disease Complex - prevention & control</subject><subject>BRD</subject><subject>Cattle</subject><subject>Disease prevention</subject><subject>Female</subject><subject>Hypotheses</subject><subject>Metaphylaxis</subject><subject>Mortality</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - administration & dosage</subject><subject>Nitric Oxide - therapeutic use</subject><subject>Prevalence</subject><subject>Prevention</subject><subject>Respiratory diseases</subject><subject>Tilmicosin</subject><subject>Tylosin - administration & dosage</subject><subject>Tylosin - analogs & derivatives</subject><subject>Tylosin - therapeutic use</subject><subject>Veterinary medicine</subject><issn>0034-5288</issn><issn>1532-2661</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks-KFDEQhxtR3NnVF_AgAS8etsck3Z10gxdZ_AcLgug5pJPKTo3dyZhkRseX9VVMM7siHhQCCamvPpLiV1VPGF0zysSL7Toeklnzcl5TXha9V61Y1_CaC8HuVytKm7bueN-fVecpbSmlLWPyYXXGJW2aoRGr6udH7W2Y8QfYS-KDr9E7iBgi5iPJEfVETJh3OqK_IZp4LHeGhO9ogUSYQKelkMK0zxg8-YZ5U7BZmximhdE-44ghlyYXYnH5XCokODKGA_pFknYYdQ7xSCymIgSCnowAjjgAO4VMjJ4OkIjOZIM3mzpi-rIYLBxgCrvlAX9actQm37keVQ-cnhI8vt0vqs9vXn-6eldff3j7_urVdW1aJnMtRzCu61sqRuh0I1oBwHune8MbN1BprGxEJ4ANhnUARhvLpW6ctWM_tmCai-r5ybuL4eseUlYzJgPTpD2EfVKsp13HOBf8_6iUcpCDGIaCPvsL3YZ99OUjRbhgQye6QvETVYaeUgSndhFnHY-KUbUkRW3VkhS1JEVRXhYtTU9v1ftxBvu75S4aBXh5AqCM7YAQVTII3oDFCCYrG_Bf_l_rEtaF</recordid><startdate>201604</startdate><enddate>201604</enddate><creator>Crepieux, T.</creator><creator>Miller, C.</creator><creator>Regev-Shoshani, G.</creator><creator>Schaefer, A.</creator><creator>Dorin, C.</creator><creator>Alexander, T.</creator><creator>Timsit, E.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201604</creationdate><title>Randomized, non-inferiority trial comparing a nitric oxide releasing solution with a macrolide antibiotic for control of bovine respiratory disease in beef feedlot calves at high-risk of developing respiratory tract disease</title><author>Crepieux, T. ; Miller, C. ; Regev-Shoshani, G. ; Schaefer, A. ; Dorin, C. ; Alexander, T. ; Timsit, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-7becf58406be5a3646ee28fa8c23f907cd73656e19c15eecacd27a3fddb8b4ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Alternative to antibiotics</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Bovine Respiratory Disease Complex - etiology</topic><topic>Bovine Respiratory Disease Complex - prevention & control</topic><topic>BRD</topic><topic>Cattle</topic><topic>Disease prevention</topic><topic>Female</topic><topic>Hypotheses</topic><topic>Metaphylaxis</topic><topic>Mortality</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - administration & dosage</topic><topic>Nitric Oxide - therapeutic use</topic><topic>Prevalence</topic><topic>Prevention</topic><topic>Respiratory diseases</topic><topic>Tilmicosin</topic><topic>Tylosin - administration & dosage</topic><topic>Tylosin - analogs & derivatives</topic><topic>Tylosin - therapeutic use</topic><topic>Veterinary medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crepieux, T.</creatorcontrib><creatorcontrib>Miller, C.</creatorcontrib><creatorcontrib>Regev-Shoshani, G.</creatorcontrib><creatorcontrib>Schaefer, A.</creatorcontrib><creatorcontrib>Dorin, C.</creatorcontrib><creatorcontrib>Alexander, T.</creatorcontrib><creatorcontrib>Timsit, E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Research in veterinary science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crepieux, T.</au><au>Miller, C.</au><au>Regev-Shoshani, G.</au><au>Schaefer, A.</au><au>Dorin, C.</au><au>Alexander, T.</au><au>Timsit, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized, non-inferiority trial comparing a nitric oxide releasing solution with a macrolide antibiotic for control of bovine respiratory disease in beef feedlot calves at high-risk of developing respiratory tract disease</atitle><jtitle>Research in veterinary science</jtitle><addtitle>Res Vet Sci</addtitle><date>2016-04</date><risdate>2016</risdate><volume>105</volume><spage>216</spage><epage>221</epage><pages>216-221</pages><issn>0034-5288</issn><eissn>1532-2661</eissn><abstract>Nitric oxide, a molecule produced in most mammalian cells, has bactericidal and virucidal properties. Nasal instillation of a nitric oxide releasing solution (NORS) on arrival at the feedlot was recently reported as non-inferior to a parenteral injection of a macrolide antibiotic, tilmicosin, for control of bovine respiratory disease (BRD) in cattle at low-to-moderate risk of developing BRD. The objective of this study was to evaluate whether NORS was non-inferior to tilmicosin for control of BRD in cattle at high-risk of developing BRD (the target population for many BRD control programs). High-risk Angus-cross heifers (n=840) were randomly allocated to 2 treatment groups on arrival at a feedlot and received either NORS or tilmicosin for BRD control. Non-inferiority was assessed by calculating the difference in prevalence of heifers diagnosed with BRD during the first 40d after arrival between NORS and tilmicosin treatment groups. The non-inferiority margin (δ) was set at 8.5%. Thirty-six and 19% of heifers were diagnosed with BRD in the NORS and tilmicosin groups, respectively. Because the lower bound of the 2-sided 95% confidence interval (CI) of the difference in BRD prevalence between the 2 treatment groups (17%; 95% CI=11–23%) was higher than δ, an inferiority of NORS was concluded. Although on-arrival nasal administration of NORS can be viewed as a more rational control strategy than parental injection of antibiotics, further research is needed to improve NORS efficacy before it can be recommended to prevent BRD in high-risk cattle.
•A nitric oxide releasing solution (NORS) has been developed for control of bovine respiratory disease (BRD).•Nasal administration of NORS was compared to parenteral injection of tilmicosin for BRD control in high-risk feedlot cattle.•36% and 19% of cattle were diagnosed with BRD during the 40 d following administration of NORS and tilmicosin, respectively.•An inferiority of NORS compared to tilmicosin was concluded.•NORS efficacy should be improved before it can be recommended to prevent BRD in high-risk cattle.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27033936</pmid><doi>10.1016/j.rvsc.2016.02.020</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0034-5288 |
ispartof | Research in veterinary science, 2016-04, Vol.105, p.216-221 |
issn | 0034-5288 1532-2661 |
language | eng |
recordid | cdi_proquest_miscellaneous_1805512262 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Alternative to antibiotics Animals Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Antibiotics Bacteria Bovine Respiratory Disease Complex - etiology Bovine Respiratory Disease Complex - prevention & control BRD Cattle Disease prevention Female Hypotheses Metaphylaxis Mortality Nitric oxide Nitric Oxide - administration & dosage Nitric Oxide - therapeutic use Prevalence Prevention Respiratory diseases Tilmicosin Tylosin - administration & dosage Tylosin - analogs & derivatives Tylosin - therapeutic use Veterinary medicine |
title | Randomized, non-inferiority trial comparing a nitric oxide releasing solution with a macrolide antibiotic for control of bovine respiratory disease in beef feedlot calves at high-risk of developing respiratory tract disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T19%3A56%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized,%20non-inferiority%20trial%20comparing%20a%20nitric%20oxide%20releasing%20solution%20with%20a%20macrolide%20antibiotic%20for%20control%20of%20bovine%20respiratory%20disease%20in%20beef%20feedlot%20calves%20at%20high-risk%20of%20developing%20respiratory%20tract%20disease&rft.jtitle=Research%20in%20veterinary%20science&rft.au=Crepieux,%20T.&rft.date=2016-04&rft.volume=105&rft.spage=216&rft.epage=221&rft.pages=216-221&rft.issn=0034-5288&rft.eissn=1532-2661&rft_id=info:doi/10.1016/j.rvsc.2016.02.020&rft_dat=%3Cproquest_cross%3E1777979699%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1877799565&rft_id=info:pmid/27033936&rft_els_id=S0034528816300431&rfr_iscdi=true |